Evotec SE (EVO)
NASDAQ: EVO · IEX Real-Time Price · USD
5.37
+0.12 (2.29%)
At close: May 2, 2024, 4:00 PM
5.34
-0.03 (-0.56%)
After-hours: May 2, 2024, 7:51 PM EDT
Evotec SE Revenue
Revenue in the quarter ending September 30, 2023 was $208.81M with 15.19% year-over-year growth. In the year 2022, Evotec SE had annual revenue of $799.41M with 13.83% growth.
Revenue (ttm)
$799.41M
Revenue Growth
+13.83%
P/S Ratio
n/a
Revenue / Employee
$161,432
Employees
4,952
Market Cap
1.90B USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 799.41M | 97.10M | 13.83% |
Dec 31, 2021 | 702.31M | 91.43M | 14.97% |
Dec 31, 2020 | 610.88M | 109.27M | 21.78% |
Dec 31, 2019 | 501.61M | 440.41M | 719.61% |
Dec 31, 2009 | 61.20M | 6.00M | 10.86% |
Dec 31, 2008 | 55.21M | 7.14M | 14.85% |
Dec 31, 2007 | 48.07M | -5.32M | -9.96% |
Dec 31, 2006 | 53.39M | 3.96M | 8.00% |
Dec 31, 2005 | 49.43M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Owens & Minor | 10.33B |
BrightSpring Health Services | 8.83B |
Amneal Pharmaceuticals | 2.39B |
Tilray Brands | 743.25M |
Galapagos NV | 266.36M |
Ginkgo Bioworks Holdings | 251.46M |
Avadel Pharmaceuticals | 27.96M |
Agios Pharmaceuticals | 26.82M |
EVO News
- 3 days ago - Bayer and Evotec Collaborate to Advance Precision Cardiology - Accesswire
- 8 days ago - Evotec shares lose a third of their value on cloudy outlook - Market Watch
- 9 days ago - Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth - Accesswire
- 9 days ago - Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer - Accesswire
- 14 days ago - Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments - Accesswire
- 14 days ago - EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS - PRNewsWire
- 15 days ago - Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024 - Accesswire
- 16 days ago - Evotec welcomes Aurélie Dalbiez as Chief People Officer - Accesswire